Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H36O2.C6H15NO3 |
| Molecular Weight | 433.6654 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCCN(CCO)CCO.CCCCCCCCCCCCCCCCCC(O)=O
InChI
InChIKey=ZHALDANPYXAMJF-UHFFFAOYSA-N
InChI=1S/C18H36O2.C6H15NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20;8-4-1-7(2-5-9)3-6-10/h2-17H2,1H3,(H,19,20);8-10H,1-6H2
| Molecular Formula | C6H15NO3 |
| Molecular Weight | 149.1882 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C18H36O2 |
| Molecular Weight | 284.4772 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionCurator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Curator's Comment: Description was created using several sources including:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/11340s16lbl.pdf; https://www.ons.org/intervention/trolamine-biafine®; https://www.ncbi.nlm.nih.gov/pubmed/?term=15084618; https://clinicaltrials.gov/ct2/show/NCT02729324; http://www.ncbi.nlm.nih.gov/pubmed/18441842
Trolamine, an organic compound, is the salt formed between triethanolamine and salicylic acid. It is widely used as a topical analgesic. 10% trolamine salicylate medical products sold over-the-counter such as are creams for temporarily relief of minor aches and pains of muscles and joints associated with arthritis, simple backache, lumbago, neuralgia, strains, bruises, and sprains. The FDA approved in 1958 otic solution drops containing triethanolamine polypeptide used in the ear to break down and loosen earwax was discontinued. Trolamine can enhance skin healing by recruiting macrophages and modifying the concentrations of various immunomodulators. Trolamine (Biafine; Genmedix Ltd, France) is commonly prescribed at the beginning of radiotherapy for preventing acute radiation-induced skin toxicity in China. Biafine has been studied in radiodermatitis and Phase 2 clinical trial has been initiated in 2016 by Sun Yat-sen University to establish the efficacy of trolamine (Biafine) for the management of radiation dermatitis in patients with nasopharyngeal carcinoma receiving IMRT.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Inactive ingredient | Volu-Firm Approved UseUnknown |
|||
| Palliative | CERUMENEX Approved UseFor removal of impacted cerumen prior to ear examination, otologic therapy and/or audiometry. CERUMENEX Eardrops should be used only with caution in external otitis. Launch Date-3.63571184E11 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 n = 15 Health Status: unhealthy Condition: Wound Age Group: 21.6–84.9 Sex: M+F Population Size: 15 Sources: |
Disc. AE: Application site erythema... AEs leading to discontinuation/dose reduction: Application site erythema (6.7%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Application site erythema | 6.7% Disc. AE |
5.38 mg 2 times / day multiple, topical Studied dose Dose: 5.38 mg, 2 times / day Route: topical Route: multiple Dose: 5.38 mg, 2 times / day Sources: |
unhealthy, 21.6–84.9 n = 15 Health Status: unhealthy Condition: Wound Age Group: 21.6–84.9 Sex: M+F Population Size: 15 Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Enantioselective separation of epoxides by capillary electrophoresis employing sulfated beta-cyclodextrin as chiral selector. | 2001 Apr |
|
| Comparative studies of various run buffers for chiral capillary electrophoresis using chiral crown ether as a chiral selector. | 2001 Dec |
|
| In vitro percutaneous absorption of tenoxicam from pressure-sensitive adhesive matrices across the hairless mouse skin. | 2001 Dec |
|
| Bis(triethanolamine)cadmium(II) and -mercury(II) saccharinates: seven-coordinate complexes containing both tri- and tetradentate triethanolamine ligands. | 2001 Dec |
|
| Vanadium, molybdenum, and sodium triethanolamine complexes derived from an assembly system containing tetrathiometalate and triethanolamine. | 2001 Jul 16 |
|
| [Determination of sulfite residues in foods by using the modified rankine apparatus and HPLC]. | 2001 Oct |
|
| Molecular changes in the expression of human colonic nutrient transporters during the transition from normality to malignancy. | 2002 Apr 22 |
|
| Quantitation of nicotine in tobacco products by capillary electrophoresis. | 2002 Jan-Feb |
|
| Synthesis and characterization of mesoporous indium tin oxide possessing an electronically conductive framework. | 2002 Jul 24 |
|
| Performances and application of a passive sampling method for the simultaneous determination of nitrogen dioxide and sulfur dioxide in ambient air. | 2002 Nov |
|
| Physiological function of the maltose operon regulator, MalR, in Lactococcus lactis. | 2002 Sep 25 |
|
| Carcinostatic, protective, and adaptive activities of tris-(2-hydroxyethyl)ammonium salts of arylheteroacetic acids. | 2002 Sep-Oct |
|
| Dynamic localization of SPE-9 in sperm: a protein required for sperm-oocyte interactions in Caenorhabditis elegans. | 2003 Dec 3 |
|
| Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope. | 2003 Feb 7 |
|
| Preliminary assessment of alginic acid as a factor buffering triethanolamine interacting with artificial skin sebum. | 2003 Mar |
|
| Synthesis of uniform anatase TiO2 nanoparticles by gel-sol method. 3. Formation process and size control. | 2003 Mar 1 |
|
| The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-beta-cyclodextrin. | 2003 Nov |
|
| Identification of selenium species in urine by ion-pairing HPLC-ICP-MS using laboratory-synthesized standards. | 2003 Oct |
|
| Determination of alkanolamines in cattails (Typha latifolia) utilizing electrospray ionization with selected reaction monitoring and ion-exchange chromatography. | 2004 |
|
| Mechanical and water barrier properties of glutenin films influenced by storage time. | 2004 Jan 14 |
|
| Rheological characterization of topical carbomer gels neutralized to different pH. | 2004 Jul |
|
| Titanatranes derailed: static and dynamic triethanolamine slippage induced by polyphenoxide chelation. | 2004 Nov 1 |
|
| Patch test results with the metalworking fluid series of the German Contact Dermatitis Research Group (DKG). | 2004 Sep |
|
| Photopolymerization of poly(ethylene glycol) diacrylate on eosin-functionalized surfaces. | 2004 Sep 28 |
|
| Frequent loss of RUNX3 gene expression in remnant stomach cancer and adjacent mucosa with special reference to topography. | 2005 Feb 14 |
Sample Use Guides
Fill ear canal with ear drops of 10% triethanolamine Polypeptide Oleate-Condensate with the patient’s head tilted at a 45° angle. Insert cotton plug and allow to remain 15-30 minutes. Then gently flush with lukewarm water, using a soft rubber syringe (avoid excessive pressure). Exposure of skin outside the ear to the drug should be avoided. The procedure may be repeated if the first application fails to clear the impaction.
Route of Administration:
Otic (auricular)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:31:57 UTC 2023
by
admin
on
Fri Dec 15 15:31:57 UTC 2023
|
| Record UNII |
1J6JM3JE61
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID9026219
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
C015555
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
224-945-5
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
4568-28-9
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
1J6JM3JE61
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
20701
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
1J6JM3JE61
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
38625
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
PRIMARY | |||
|
1314215
Created by
admin on Fri Dec 15 15:31:57 UTC 2023 , Edited by admin on Fri Dec 15 15:31:57 UTC 2023
|
ALTERNATIVE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |